Reynders McVeigh Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$336K Sell
11,972
-1,131
-9% -$30.1K 0.02% 153
2025
Q4
$326K Sell
13,103
-2,770
-17% -$69.9K 0.02% 154
2025
Q3
$404K Sell
15,873
-1,935
-11% -$47.8K 0.02% 139
2025
Q2
$432K Sell
17,808
-1,606
-8% -$37.5K 0.02% 141
2025
Q1
$492K Sell
19,414
-1,932
-9% -$50.6K 0.03% 137
2024
Q4
$566K Sell
21,346
-600
-3% -$16.3K 0.03% 134
2024
Q3
$635K Buy
21,946
+2,100
+11% +$61.3K 0.03% 132
2024
Q2
$555K Sell
19,846
-1,535
-7% -$42.3K 0.03% 135
2024
Q1
$594K Sell
21,381
-370
-2% -$10.3K 0.03% 130
2023
Q4
$626K Sell
21,751
-7,209
-25% -$218K 0.04% 123
2023
Q3
$961K Sell
28,960
-4,817
-14% -$170K 0.07% 92
2023
Q2
$1.24M Sell
33,777
-1,726
-5% -$67.2K 0.08% 87
2023
Q1
$1.45M Buy
35,503
+3,117
+10% +$135K 0.1% 80
2022
Q4
$1.66M Sell
32,386
-2,946
-8% -$141K 0.12% 76
2022
Q3
$1.55M Buy
35,332
+1,859
+6% +$90.3K 0.12% 79
2022
Q2
$1.75M Sell
33,473
-3,653
-10% -$186K 0.13% 74
2022
Q1
$1.92M Sell
37,126
-1,448
-4% -$75.1K 0.12% 78
2021
Q4
$2.28M Sell
38,574
-500
-1% -$24.8K 0.13% 77
2021
Q3
$1.68M Buy
39,074
+357
+0.9% +$15.8K 0.1% 88
2021
Q2
$1.52M Sell
38,717
-20,843
-35% -$811K 0.09% 92
2021
Q1
$2.16M Buy
59,560
+7,288
+14% +$259K 0.14% 78
2020
Q4
$1.92M Sell
52,272
-9,776
-16% -$359K 0.13% 71
2020
Q3
$2.16M Sell
62,048
-4,058
-6% -$142K 0.17% 64
2020
Q2
$2.05M Sell
66,106
-1,668
-2% -$56.7K 0.18% 64
2020
Q1
$2.1M Buy
67,774
+717
+1% +$24.4K 0.24% 62
2019
Q4
$2.49M Sell
67,057
-1,259
-2% -$44.8K 0.24% 63
2019
Q3
$2.33M Buy
68,316
+8,127
+14% +$296K 0.25% 63
2019
Q2
$2.47M Sell
60,189
-1,388
-2% -$55.1K 0.27% 62
2019
Q1
$2.48M Buy
61,577
+3,780
+7% +$151K 0.27% 64
2018
Q4
$2.39M Sell
57,797
-1,777
-3% -$73.8K 0.32% 60
2018
Q3
$2.49M Sell
59,574
-3,317
-5% -$128K 0.29% 61
2018
Q2
$2.17M Buy
62,891
+9,553
+18% +$326K 0.28% 64
2018
Q1
$1.8M Buy
53,338
+3,103
+6% +$107K 0.23% 68
2017
Q4
$1.73M Sell
50,235
-646
-1% -$22K 0.23% 72
2017
Q3
$1.72M Sell
50,881
-1,960
-4% -$63K 0.22% 72
2017
Q2
$1.68M Sell
52,841
-325
-0.6% -$10.2K 0.23% 73
2017
Q1
$1.73M Sell
53,166
-584
-1% -$18.4K 0.24% 78
2016
Q4
$1.66M Sell
53,750
-2,896
-5% -$88.4K 0.24% 77
2016
Q3
$1.82M Buy
56,646
+392
+0.7% +$13.1K 0.27% 67
2016
Q2
$1.88M Buy
56,254
+5,212
+10% +$166K 0.27% 71
2016
Q1
$1.44M Buy
51,042
+2,012
+4% +$57.5K 0.21% 82
2015
Q4
$1.5M Sell
49,030
-3,837
-7% -$121K 0.25% 67
2015
Q3
$1.57M Sell
52,867
-5,197
-9% -$167K 0.27% 62
2015
Q2
$1.85M Buy
58,064
+350
+0.6% +$11.4K 0.3% 55
2015
Q1
$1.91M Buy
57,714
+4,301
+8% +$137K 0.33% 49
2014
Q4
$1.58M Buy
53,413
+787
+1% +$22.6K 0.28% 59
2014
Q3
$1.48M Sell
52,626
-30
-0.1% -$842 0.28% 61
2014
Q2
$1.48M Buy
52,656
+6,846
+15% +$195K 0.34% 57
2014
Q1
$1.4M Buy
45,810
+1,950
+4% +$58.1K 0.33% 60
2013
Q4
$1.27M Hold
43,860
0.32% 62
2013
Q3
$1.2M Sell
43,860
-80
-0.2% -$2.18K 0.33% 61
2013
Q2
$1.17M Buy
+43,940
New +$1.21M 0.35% 63

Other funds holding PFE

Reynders McVeigh Capital Management's PFE Position: Q1 2026 in Review

Reynders McVeigh Capital Management reduced its Pfizer (PFE) stake by 8.6% in Q1 2026, selling an estimated $30.1K and leaving 11,972 shares worth $336K. The position accounts for 0.02% of the portfolio, ranked #153.

Reynders McVeigh Capital Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.49M in Q4 2019. 2,955 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Reynders McVeigh Capital Management held 11,972 shares of Pfizer worth $336K as of Q1 2026.
  • Reynders McVeigh Capital Management sold 1,131 Pfizer shares in Q1 2026, an estimated $30.1K.
  • Pfizer made up 0.02% of Reynders McVeigh Capital Management's portfolio in Q1 2026, its #153 holding.
  • Reynders McVeigh Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Reynders McVeigh Capital Management's Pfizer position peaked at $2.49M in Q4 2019.
  • 2,955 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.